Strategic Research

Bacterial Pathogenesis and Antimicrobials (PatoBAnt)

The main objective of our research group is the development of new strategies to combat infections by multidrug-resistant (MDR) bacteria, in particular of the gram-negative (GN) group. Our team combines a range of computational and experimental techniques for the identification of vaccine-antigen and antimicrobial-target candidates with new modes of action. Much of this research is done in collaboration with the group of Bacterial Molecular Genetics of IBB, led by Dr. Isidre Gibert. Specifically, we are engaged in the following types of activities:

  • Development of bioinformatic methods for the identification of novel antimicrobial-drug targets, antigens and their epitopes in pathogenic bacteria.
  • Experimental validation and characterisation of identified antigens and antimicrobial-drug targets.
  • Biomolecular modelling and simulation for the design of synthetic vaccines.
  • Target-based virtual screening for antimicrobial-drug discovery.
  • Experimental validation of hit antimicrobial compounds.

Main projects

  • 1.

    Non-essential biological processes in Stenotrophomonas maltophilia as targets for the design of new antimicrobial strategies.

    This project concerns the search and characterization of targets involved in the modulation of virulence and resistance in Stenotrophomonas maltophilia, an opportunistic, emerging nosocomial pathogen that shows intrinsic resistance to multiple antibiotics and can produce a broad clinical spectrum of infections. MINECO Ref. BIO2015-66674.



Bioinformatics expertise:

Group Leader:

Xavier Daura